CNS Pharmaceuticals Inc. (NASDAQ: CNSP), a biopharmaceutical company dedicated to developing treatments for brain and central nervous system cancers, has announced a 1-for-12 reverse stock split set to take effect on July 22, 2025. This strategic move will see every twelve shares of the company’s common stock converted into one share, with corresponding adjustments made to warrants and equity awards. The company’s stock will continue to trade under the symbol CNSP but will be assigned a new CUSIP number: 18978H508.

The reverse stock split is designed to uniformly affect all shareholders, with no fractional shares being issued. Instead, shareholders who would otherwise receive fractional shares will be compensated in cash. Additionally, the authorized share count will be reduced to 25 million, while the par value per share will remain unchanged at $0.001. This decision reflects the company’s efforts to streamline its capital structure and potentially make its stock more attractive to investors by increasing the share price.

CNS Pharmaceuticals Inc. is at the forefront of developing innovative treatments for aggressive and often incurable forms of brain cancer, including glioblastoma multiforme (GBM). The company’s lead drug candidate, Berubicin, represents a significant advancement in oncology as the first anthracycline believed to cross the blood-brain barrier, offering hope for patients with serious brain and CNS oncology indications.

For further details on the reverse stock split and other company updates, interested parties can view the full press release here. CNS Pharmaceuticals Inc. continues to focus on its mission to address unmet medical needs in the treatment of brain and CNS cancers, with Berubicin at the core of its promising pipeline.

This news story relied on content distributed by None. Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is CNS Pharmaceuticals Inc. Announces 1-for-12 Reverse Stock Split.